Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service breast reconstruction cases in California: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 17% on average (125 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 11 | 1,813 | 48% |
| 2020 | 14 | 1,468 | 50% |
| 2021 | 9 |
Implant- and flap-based reconstruction; ADM and expander call point. Professional codes (what the surgeon bills): CPT 19357, 19340, 19342, 19364, 19380.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 88% of the cases CMS names in California; 9 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Arizona | 2 | 390−7.9%/yr | −7.9%/yr | 0.5 | 11% | 540 in 2030+5.6%/yr |
| Washington | 0 | 328 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Hernia repair | 233 | 17,286−1.1%/yr | −1.1%/yr | 5.50.8× | 15% | 19,300 in 2030+1.8%/yr |
| Cholecystectomy & appendectomy |
Breast reconstruction in every state, and its device makers · Every procedure market in California · Every state · Compare with Arizona
| 2024 |
| 1,522 |
| 56% |
| 2025 est. | ≈ 1,900 | – |
| 2026 est. | ≈ 1,930 | – |
| 1,484 |
| 52% |
| 2022 | 7 | 1,532 | 53% |
| 2023 | 11 | 1,456 | 55% |
| 2024 | 12 | 1,522 | 56% |
| 2025 from claims | – | 1,897 1,741–2,007 | 56% |
| 2026 forecast | – | 1,933 1,701–2,230 | 56% |
| 2027 forecast | – | 1,958 1,674–2,333 | 56% |
| 2028 forecast | – | 1,984 1,655–2,429 | 56% |
| 2029 forecast | – | 2,010 1,641–2,520 | 57% |
| 2030 forecast | – | 2,036 1,631–2,609 | 57% |
In 2025, 11% inpatient hospital, 89% hospital outpatient. The share outside the hospital has moved −9 pts since 2019.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| −9.3%/yr |
| 0.4 |
| 22% |
| 330 in 2030−0.1%/yr |
| Colorado | 0 | 223−9.1%/yr | −9.1%/yr | 0.5 | 0% | 230 in 2030+0.5%/yr |
| Utah | 0 | 128−2.1%/yr | −2.1%/yr | 0.6 | 0% | 650 in 2030+31%/yr |
| Oregon | 0 | 119−15%/yr | −15%/yr | 0.3 | 48% | 130 in 2030+1.7%/yr |
| 221 |
| 11,459−2.6%/yr |
| −2.6%/yr |
| 3.50.9× |
| 2% |
| 12,600 in 2030+1.6%/yr |
| Colorectal resection | 16 | 4,592−1.4%/yr | −1.4%/yr | 1.41.0× | 0% | 5,470 in 2030+3%/yr |
| Antireflux & hiatal hernia surgery | 37 | 2,040+1.2%/yr | +1.2%/yr | 0.60.8× | 0% | 2,990 in 2030+6.6%/yr |
| Bariatric surgery | 3 | 481−12%/yr | −12%/yr | 0.10.8× | 0% | 400 in 2030−3.2%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Abbvie leads with 52% of company spending on these surgeons in 2025, −3 pts on 2024.
In 2025, 12 companies reported engagement with California’s surgeons worth $654K in consulting, speaking, meals and travel tied to these products, about $55K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 20 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.